Spectrila
What Spectrila is used for
Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Spectrila
- Active substance
- asparaginase
- Disease area
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX02
- Marketing authorisation holder
- Medac Gesellschaft fuer klinische Spezialpraeparate mbH
- Authorised in the EU since
- 2016
Official information
In the USA
Same active substance: Rylaze
In India
- Asparaginase: 28 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Spectrila used for?
Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
What is the active substance in Spectrila?
Spectrila contains asparaginase.
Who makes Spectrila?
The EU marketing authorisation holder is Medac Gesellschaft fuer klinische Spezialpraeparate mbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU